187 related articles for article (PubMed ID: 29293218)
1. Making cancer immunotherapy a surer bet.
Eisenstein M
Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
[No Abstract] [Full Text] [Related]
2. The struggle to do no harm in clinical trials.
Schmidt C
Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235
[No Abstract] [Full Text] [Related]
3. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
Patel J; Crawford JM
Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
[No Abstract] [Full Text] [Related]
4. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
5. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
6. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
7. Thymic malignancies: Twisting between autoimmunity and immunotherapy.
Girard N
Lung Cancer; 2017 Aug; 110():68-70. PubMed ID: 28526140
[No Abstract] [Full Text] [Related]
8. Immunotherapy in Lung Cancer.
Du L; Herbst RS; Morgensztern D
Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
[TBL] [Abstract][Full Text] [Related]
9. Combining Chemotherapy and Immunotherapy for the Treatment of Triple-Negative Breast Cancer.
McArthur H
Oncology (Williston Park); 2019 Apr; 33(4):137-40. PubMed ID: 30990566
[No Abstract] [Full Text] [Related]
10. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
11. A future boost for anti-PD1 responses.
Stower H
Nat Med; 2020 Sep; 26(9):1331. PubMed ID: 32908280
[No Abstract] [Full Text] [Related]
12. Cancer treatment: The killer within.
Ledford H
Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
[No Abstract] [Full Text] [Related]
13. Part I: Checkpoint inhibitors in cancer therapy.
Daud AI
Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
[No Abstract] [Full Text] [Related]
14. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
15. Tumor Immunology and Tumor Evolution: Intertwined Histories.
Galon J; Bruni D
Immunity; 2020 Jan; 52(1):55-81. PubMed ID: 31940273
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy in patients with preexisting autoimmune disorders.
Donia M; Pedersen M; Svane IM
Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
[TBL] [Abstract][Full Text] [Related]
17. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials.
Upadhaya S; Neftelino ST; Hodge JP; Oliva C; Campbell JR; Yu JX
Nat Rev Drug Discov; 2021 Mar; 20(3):168-169. PubMed ID: 33177720
[No Abstract] [Full Text] [Related]
18. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
19. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
[TBL] [Abstract][Full Text] [Related]
20. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]